GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaxart Inc (STU:NB11) » Definitions » Cyclically Adjusted PS Ratio

Vaxart (STU:NB11) Cyclically Adjusted PS Ratio : 0.37 (As of Sep. 23, 2024)


View and export this data going back to . Start your Free Trial

What is Vaxart Cyclically Adjusted PS Ratio?

As of today (2024-09-23), Vaxart's current share price is €0.772. Vaxart's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2024 was €2.07. Vaxart's Cyclically Adjusted PS Ratio for today is 0.37.

The historical rank and industry rank for Vaxart's Cyclically Adjusted PS Ratio or its related term are showing as below:

STU:NB11' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.02   Med: 0.4   Max: 1.49
Current: 0.37

During the past years, Vaxart's highest Cyclically Adjusted PS Ratio was 1.49. The lowest was 0.02. And the median was 0.40.

STU:NB11's Cyclically Adjusted PS Ratio is ranked better than
92.69% of 465 companies
in the Biotechnology industry
Industry Median: 5.31 vs STU:NB11: 0.37

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Vaxart's adjusted revenue per share data for the three months ended in Jun. 2024 was €0.032. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €2.07 for the trailing ten years ended in Jun. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Vaxart Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Vaxart's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vaxart Cyclically Adjusted PS Ratio Chart

Vaxart Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 0.65 0.96 - 0.15

Vaxart Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.15 0.15 0.50 0.30

Competitive Comparison of Vaxart's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Vaxart's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vaxart's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vaxart's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Vaxart's Cyclically Adjusted PS Ratio falls into.



Vaxart Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Vaxart's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=0.772/2.07
=0.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vaxart's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2024 is calculated as:

For example, Vaxart's adjusted Revenue per Share data for the three months ended in Jun. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=0.032/132.5538*132.5538
=0.032

Current CPI (Jun. 2024) = 132.5538.

Vaxart Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201409 0.171 100.428 0.226
201412 3.533 99.070 4.727
201503 1.706 99.621 2.270
201506 1.112 100.684 1.464
201509 0.432 100.392 0.570
201512 0.444 99.792 0.590
201603 1.355 100.470 1.788
201606 0.127 101.688 0.166
201609 0.025 101.861 0.033
201612 1.025 101.863 1.334
201703 1.304 102.862 1.680
201706 0.025 103.349 0.032
201709 0.024 104.136 0.031
201712 0.649 104.011 0.827
201803 0.230 105.290 0.290
201806 0.073 106.317 0.091
201809 0.034 106.507 0.042
201812 0.217 105.998 0.271
201903 0.655 107.251 0.810
201906 0.005 108.070 0.006
201909 0.025 108.329 0.031
201912 0.073 108.420 0.089
202003 0.043 108.902 0.052
202006 0.006 108.767 0.007
202009 0.002 109.815 0.002
202012 0.003 109.897 0.004
202103 0.004 111.754 0.005
202106 0.001 114.631 0.001
202109 0.001 115.734 0.001
202112 0.001 117.630 0.001
202203 0.001 121.301 0.001
202206 0.000 125.017 0.000
202209 0.000 125.227 0.000
202212 0.000 125.222 0.000
202303 0.002 127.348 0.002
202306 0.000 128.729 0.000
202309 0.003 129.860 0.003
202312 0.043 129.419 0.044
202403 0.012 131.776 0.012
202406 0.032 132.554 0.032

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Vaxart  (STU:NB11) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Vaxart Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Vaxart's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Vaxart Business Description

Industry
Traded in Other Exchanges
Address
170 Harbor Way, Suite 300, South San Francisco, CA, USA, 94080
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.

Vaxart Headlines

No Headlines